Identification and characterisation of a salt form of Danirixin with reduced pharmacokinetic variability in patient populations
The natural variability of gastric pH or gastric acid reducing medications can result in lower and more variable clinical pharmacokinetics for basic compounds in patient populations.
Unit Operation: Dissolution
Objective: Characterization
Company: GSK
Source: European Journal of Pharmaceutics and Biopharmaceutics
Authors: Claire Ambery (GSK), Jackie C. Bloomer (GSK), Paul Connolly (GSK), Helen Garden (GSK), Nick Henley (GSK), Neil Hodnett (GSK), Sarah Keel (GSK), James L. Kreindler (GSK), Aili L. Lazaar (GSK), Richard S. Lloyd (GSK), Wayne Matthews (GSK), Bruce E. Miller (GSK), John Yonchuk (GSK)
Publish Date: 03-Apr-2017
Copyright © 2018 Scale-up Systems Ltd. | DynoChem Software and Development Services for the Pharma Industry | Privacy | Cookies | Contact